Gas Plasma Technology-An Asset to Healthcare During Viral Pandemics Such as the COVID-19 Crisis?

IEEE Trans Radiat Plasma Med Sci. 2020 Jun 16;4(4):391-399. doi: 10.1109/TRPMS.2020.3002658. eCollection 2020 Jul.

Abstract

The COVID-19 crisis profoundly disguised the vulnerability of human societies and healthcare systems in the situation of a pandemic. In many instances, it became evident that the quick and safe reduction of viral load and spread is the foremost principle in the successful management of such a pandemic. However, it became also clear that many of the established routines in healthcare are not always sufficient to cope with the increased demand for decontamination procedures of items, healthcare products, and even infected tissues. For the last 25 years, the use of gas plasma technology has sparked a tremendous amount of literature on its decontaminating properties, especially for heat-labile targets, such as polymers and tissues, where chemical decontamination often is not appropriate. However, while the majority of earlier work focused on bacteria, only relatively few reports are available on the inactivation of viruses. We here aim to provide a perspective for the general audience of the chances and opportunities of gas plasma technology for supporting healthcare during viral pandemics such as the COVID-19 crisis. This includes possible real-world plasma applications, appropriate laboratory viral test systems, and critical points on the technical and safety requirements of gas plasmas for virus inactivation.

Keywords: Airborne virus; DBD; cold atmospheric pressure plasma; decontamination; plasma jet; transmission.

Grants and funding

The work of Sander Bekeschus and Thomas von Woedtke was supported in part by the German Federal Ministry of Education and Research (BMBF) under Grant 03Z22DN11, Grant 03Z22DN12, and Grant 03Z22Di1, and in part by the European Social Fund under Grant ESF/14-BM-A55-0006-18. The work of Elisabetta Suffredini was supported by the MIUR PRIN 2017 Project PlasmaFood. The work of Vittorio Colombo was supported in part by the 2014–2020 European Regional Development Fund Emilia-Romagna Regional Operational Program on industrial research and innovation projects for contrast solutions to the spread of COVID-19—Project VIKI (VIrus KIller) and in part by the MIUR PRIN 2017 Project PlasmaFood.